Table 2.
Antimicrobial peptides for infectious diseases indications in ongoing clinical trials.
| Phase | Peptide name | Identifier numbers | Condition | Administration route |
|---|---|---|---|---|
| II | NP213 (Novexatin) | NCT02933879 | Fungal nail infection | Topical |
| PAC-113 | NCT00659971 | Oral candidiasis in HIV patients | Topical | |
| MBI-226 | NCT00211523 | Acne vulgaris and acne | Topical | |
| Dalbavancin | NCT02685033 | Acute hematogenous osteomyelitis | Intravenous | |
| Brilacidin | NCT02052388 | Skin and bacterial infection | Topical | |
| CLS001 (Omiganan) | NCT02596074 | Acne vulgaris | Topical | |
| III | Pexiganan (MSI-78) | NCT01594762 | Diabetic foot infection | Topical |
| Surotomycin | NCT01597505 | Clostridium difficile associated diarrhea | Oral | |
| CLS001 (Omiganan) | NCT02576847 | Papulopustular rosacea | Topical | |
| P2TA | NCT01417780 | Necrotizing soft tissue infection | Intravenous | |